While Catalyst Pharmaceuticals Inc has overperformed by 2.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CPRX rose by 70.53%, with highs and lows ranging from $24.64 to $13.12, whereas the simple moving average jumped by 19.65% in the last 200 days.
On February 04, 2025, Robert W. Baird started tracking Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) recommending Outperform. A report published by Stephens on November 18, 2024, Initiated its previous ‘Overweight’ rating for CPRX. Citigroup also rated CPRX shares as ‘Buy’, setting a target price of $27 on the company’s shares in an initiating report dated March 14, 2024. BofA Securities Initiated an Buy rating on March 07, 2024, and assigned a price target of $23. Oppenheimer initiated its ‘Outperform’ rating for CPRX, as published in its report on December 21, 2023. ROTH Capital’s report from August 24, 2022 suggests a price prediction of $15.50 for CPRX shares, giving the stock a ‘Neutral’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Further, the quarter-over-quarter increase in sales is 25.33%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Catalyst Pharmaceuticals Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 28.29% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.92, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.08M can be a very valuable indicator of volatility for CPRX stock. On a monthly basis, the volatility of the stock is set at 3.72%, whereas on a weekly basis, it is put at 2.49%, with a gain of 0.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.22, showing growth from the present price of $23.26, which can serve as yet another indication of whether CPRX is worth investing in or should be passed over.
How Do You Analyze Catalyst Pharmaceuticals Inc Shares?
The USA based company Catalyst Pharmaceuticals Inc (CPRX) is one of the biggest names in Biotechnology. When comparing Catalyst Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 19.84, there is a growth in quarterly earnings of 221.20%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.65%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 79.15% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CPRX shares are owned by institutional investors to the tune of 79.15% at present.
